Table 2B,
Incremental Cost Effectiveness Ratios – Base Case and Alternate Scenarios
| ICER | ||
|---|---|---|
| DCT vs ADT | DCT vs AA | |
| Main Model (PF-QALYs) | $50,489 | $1,009,975 |
| No QALY adjustment (PF-LYs) | $44,368 | $969,532 |
| Model VA price (PF-QALYs) | $50,489 | $575,031 |
| Model with 1/4 dose (PF-QALYs) | $50,489 | $208,062 |